Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Napp Pharmaceutical Group Ltd.
NICE says final fast-tracked yes to Napp's Levact
NICE, the health technology appraisal institute for England and Wales, has given a final thumbs up to Napp Pharmaceuitcals's Levact (bendamustine) for some patients with chronic lymphocytic leukaemia (CLL).
Napp impresses NICE with Levact evidence
NICE, the health technology appraisal institute for England and Wales, has today recommended Napp's chemotherapy drug Levact (bendamustine) for treating patients with chronic lymphocytic leukaemia. The institute was so impressed with the strength of the evidence supporting the product that it jumped Levact straight to the final stages of guidance development.
New appointment at Napp Pharmaceuticals
Rachel Cummings has been appointed health policy and advocacy manager in the UK corporate affairs department at Napp Pharmaceuticals. She joins from Racepoint Group, where she was associate director.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice